EUCTR2019-003360-45-FR进行中（未招募）1 期
Effect of impact of PCSK9 inhibitor on coronary microvascular dysfunction in patients with atherosclerotic cardiovascular disease proved by myocardial ischemia and needing coronarography. - MICROPROTECT
niversity Hospital Grenoble0 个研究点目标入组 66 人开始时间: 2019年12月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male or female patient, aged 40 to 85,
- •-More than 50 kilograms
- •-Defined at high cardiovascular risk according to European guidelines
- •-LDL-C level = 0.7 g / L (biological assessment of less than 6 months)
- •-Having benefited from myocardial scintigraphy
- •-For which coronarography is indicated according to European guidelines
- •-Affiliated with social security,
- •-Signed informed consent form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 33
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 33
排除标准
- •-Clinical presentation of unstable angina
- •-Patient whose state of physical or psychological health could compromise the obtaining of his informed consent and his compliance with the requirements of the protocol, with the study evaluation, procedures or completion.
- •-End stage disease (estimated survival of less than one year)
- •-Severe renal dysfunction, defined as an estimated creatinine clearance (MDRD) < 30 mL/min at screening
- •-Contra-indication to adenosin : hypersensitivity to active active substance or to any of the excipients, type II or III atrioventricular block or atrial disease (except for pacemaker users), long QT syndrome, severe arterial hypotension, acute heart failure, asthma and severe chronic obstructive pulmonary disease, unstable angina unstabilized by drug therapy, taking dipyridamole, aminophylline, theophylline or other xanthine base within 24 hours prior to adenosine administration
- •-Contra-indication to heparin: hypersensitivity to active substance or to any of the excipients, past heparin induced thrombopenia type II, haemorrhage.
- •-Prior CABG
- •-Prior myocardial infarction in the territory of ischemia
- •-NYHA class III or IV, or last known left ventricular ejection fraction < 30%
- •-Known hemorrhagic stroke at any time
- •-Uncontrolled or recurrent ventricular tachycardia
- •-Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) > 180 mmHg or diastolic BP (DBP) > 110 mmHg
- •-Actual use of PCSK9 inhibitior (evolucumab or others)
- •-Untreated or inadequately treated hyperthyroidism or hypothyroidism, controlled by biological assessment if needed, defined by thyroid stimulating hormone (TSH) < lower limit of normal (LLN) or > 1.5 times the upper limit of normal (ULN), respectively, and free thyroxine (T4) levels that are outside normal range at screening
- •-Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the ULN at screening
- •-Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow, renal)
- •-Personal or family history of hereditary muscular disorders
- •-LDL apheresis within 12 months prior to randomization
- •-CPK> 5 ULN at screening
- •- Active infection or others active disease judge by investigator incompatible with the protocole completion
- •-Main known active infection including positive viral serology (HIV, HBV and HCV)
- •-Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma) within the last 10 years
- •-Known sensitivity to evolocumab or their excipients to be administered during dosing or natural rubber / latex
- •-Patient likely to not be available to complete all protocol-required study visits or procedures.
- •-Patient in exclusion period of another study
- •-Woman able to procreate in the absence of highly effective contraception
- •-Persons referred to in Articles L1121-6 to L1121-8 of the French code of public health (this corresponds to all persons protected: pregnant or parturient women, breastfeeding mothers, persons deprived of liberty by judicial or administrative decision, persons subject to a legal protection measure).
研究者
相似试验
招募中
4 期
Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence TomographyOptical Coherence TomographyCoronary Artery DiseaseNCT06520904First Affiliated Hospital of Xinjiang Medical University396
Unknown
2 期
Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing CoronarographyAtherosclerotic Cardiovascular DiseaseNCT04338165University Hospital, Grenoble66
已完成
4 期
Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence TomographyRandomized Controlled TrialsNCT04851769Beijing Anzhen Hospital60
招募中
不适用
Impact of PCSK9 Inhibitor on the Characteristics of Lipid-rich Coronary Plaques Assessed by Near-infrared SpectroscopyIschemic Heart DiseaseJPRN-UMIN000040318Gifu Heart Center50
Unknown
不适用
PCSK9 Inhibitor on ACS Patients With Multivessel Disease and Relatively Low LDL-C Level in Chinese PopulationAcute Coronary SyndromeNCT05043740Second Xiangya Hospital of Central South University1,360